Compare VMI & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMI | ARWR |
|---|---|---|
| Founded | 1946 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 10.2B |
| IPO Year | 1994 | 2009 |
| Metric | VMI | ARWR |
|---|---|---|
| Price | $541.50 | $72.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $500.33 | $83.40 |
| AVG Volume (30 Days) | 209.7K | ★ 2.0M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.63% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 5.51 | N/A |
| Revenue | ★ $3,169,556,000.00 | $16,142,321.00 |
| Revenue This Year | $5.53 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $98.23 | ★ N/A |
| Revenue Growth | ★ 14.52 | N/A |
| 52 Week Low | $326.22 | $14.30 |
| 52 Week High | $585.71 | $87.83 |
| Indicator | VMI | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 37.28 |
| Support Level | $391.12 | $70.05 |
| Resistance Level | $548.90 | $74.60 |
| Average True Range (ATR) | 15.10 | 4.17 |
| MACD | -4.92 | -1.22 |
| Stochastic Oscillator | 24.89 | 0.25 |
Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting, transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.